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Abstract: ABCB1/P-glycoprotein is an ATP binding cassette transporter that is involved in the
clearance of xenobiotics, and it affects the disposition of many drugs in the body. Conformational
flexibility of the protein within the membrane is an intrinsic part of its mechanism of action, but
this has made structural studies challenging. Here, we have studied different conformations of
P-glycoprotein simultaneously in the presence of ivacaftor, a known competitive inhibitor. In order
to conduct this, we used high contrast cryo-electron microscopy imaging with a Volta phase plate.
We associate the presence of ivacaftor with the appearance of an additional density in one of the
conformational states detected. The additional density is in the central aqueous cavity and is
associated with a wider separation of the two halves of the transporter in the inward-facing state.
Conformational changes to the nucleotide-binding domains are also observed and may help to
explain the stimulation of ATPase activity that occurs when transported substrate is bound in many
ATP binding cassette transporters.
Keywords: P-glycoprotein; ABCB1; ABCC7; ABC transporter; ivacaftor; drug binding; Volta
phase plate
1. Introduction
P-glycoprotein (P-gp) is an ATP-dependent multi-drug transporter of the ATP-binding
cassette (ABC) family that is involved in the active efflux of many drugs and xenobiotics
from cells [1]. Overexpression or activation of P-gp can lead to multi-drug resistance in
cancer cells [2–5]. Drugs and inhibitors are thought to bind to the inward-facing con-
formation of P-gp [6–9], which is more favored in the post hydrolytic or nucleotide-free
conditions [10–12]. The drug is then translocated across the plasma membrane by transition
of the protein to the outward-facing state, which is more favored when ATP is bound [12].
The dynamic conformational nature of P-gp (and other ABC family members [13]) has
challenged structural studies. Nevertheless, P-gp structures have been obtained by X-ray
crystallography [14–18] and cryo-electron microscopy (cryo-EM) [7–9,19–21]. Stabilizing
antibodies and ATP hydrolysis-inactivating mutations have been exploited to generate
~4 Å resolution structural data by cryo-EM [7,9,19]. Similarly, trapping the protein in a post-
hydrolytic state with vanadate and ATP yielded an ~8 Å resolution structure [21]. However,
under these experimental conditions, allosteric changes could be altered or inhibited.
Recent studies have demonstrated that the novel cystic fibrosis (CF) therapeutic
ivacaftor is a competitive inhibitor or transported substrate of P-gp [22,23]. This drug is a
potentiator of the channel activity of an P-gp homolog, the cystic fibrosis transmembrane
Membranes 2021, 11, 923. https://doi.org/10.3390/membranes11120923 https://www.mdpi.com/journal/membranes
Membranes 2021, 11, 923 2 of 14
conductance regulator CFTR/ABCC7 [24], and ivacaftor is now widely used in the clinic,
both on its own as well as in combination with CFTR-corrector compounds such that
roughly 90% of CF patients may now be treatable [25,26]. A prior structure for ivacaftor
bound to CFTR showed the binding mode of the drug, which was on the external surface
of the membrane-spanning region and within the hydrophobic region of the detergent
micelle [27]. The drug itself is highly hydrophobic and was used at a relatively high
concentration, but mutagenesis studies and experiments with another potentiator drug
with a slightly different structure were undertaken to provide further evidence that the
position of the drug in CFTR represented a common binding mode. A further interesting
observation in the study was that there was minimal conformational change upon drug
binding, and because of the rigid nature of the drug, conformational selection (of the
drug) may not occur. Structure–activity relationships (SAR) of ivacaftor homologs with
potentiating and inhibiting properties identified the quinoline nitrogen as crucial for activity
via hydrogen bonding. π-π stacking with nearby residues by the same quinoline group
was also found to be important. The planar nature of the drug was also shown to be a
significant factor in the SAR study. The hydroxyl group of the hydroxyphenyl moiety is
polar with a computed pKa of 11 (CHEMBL2010601) and points towards the guanidino
group of R933 in the structural model [24,27], implying polar interactions that are too
distant (6 Å) for hydrogen bonding.
In this study, we examined the P-gp structure in the presence of ivacaftor. In order
to minimize non-specific binding of the hydrophobic drug, we employed a concentration
likely to be encountered in vivo [28] and at a sub-stoichiometric ratio with the protein.
This approach had the advantage of allowing both drug-bound and drug-free forms of
the protein to coexist as a mixture in the protein/drug solution immediately prior to
flash freezing and cryo-electron microscopy. We reasoned that if drug binding caused a
conformational change in P-gp, we should be able to distinguish different conformations
using 3D classification of the particles. If no major change in the overall 3D structure
occurred (as was the case for CFTR [27,29]), we expected to obtain a single 3D structure
but with fractional occupancy of the drug at its binding site, leading to weak density
for ivacaftor in the experimental 3D density map. A third possibility existed: that drug
binding would cause conformational changes, but that discrimination of these different
conformations would not be possible by the image processing routines. In this case, we
would expect a smeared, low-resolution 3D map for the protein with no information about
drug binding. In order to minimize the chances of the latter scenario, we employed the
Volta phase plate to collect very high signal:noise data with minimal under focus. There are
difficulties in the use of the Volta phase plate that restrict its current wide application [29],
and there are currently only a few examples of studies resulting in resolution better
than 3 Å [29]. Nevertheless, previous studies with 3D maps of resolution similar to those
reported here have allowed drugs and small ligands such as sterols and nucleotides to be
positioned and their binding interactions modeled within the protein of interest [30–42].
In this report, we aim to compare apo and drug-bound states within a single cryo-EM
specimen. If successful, the approach we describe should minimize specimen preparation
and biological variation as well as allowing relatively physiological levels of drugs to
be employed.
2. Materials and Methods
P. pastoris harboring the opti-mdr3 gene was kindly provided by Prof. Ina L. Urbatsch,
Texas Tech University [43]. Cell culture was performed using the shake-flask method
described by Beaudet and co-workers with minor modifications [44]. Overexpression of
the gene product (abcb1a) was initiated by the addition of methanol, and the expression
was prolonged following an optimized procedure [21]. Cell pellets were collected and
stored at −80 ◦C.
Cell rupture was conducted using glass bead beating, and microsomal membranes
were prepared as described in (4). Microsomal membranes were diluted to 2.5 mg/mL
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prior to solubilization in detergent-containing buffer (50 mM Tris pH 8.0, 10% (v/v) glycerol,
50 mM NaCl, 1 mM 2-mercaptoethanol and 2% (w/v) DDM). Solubilized materials were
processed through multi-step protein purification, described previously [21,22]. Purified
protein was concentrated to 5–10 mg/mL using a Vivaspin concentrator with 100-kDa
cut-off, flash-frozen in liquid nitrogen, and stored at −80 ◦C.
Drug binding and P-gp thermostability were assayed in 3 ways using an UNCLE
(Unchained laboratories) instrument: concentrated P-gp protein (1 µg per sample) was
diluted into 10 µL of buffer (100 mM Tris-HCl pH 8, 150 mM NaCl, 10% glycerol, 0.1%
DDM and 0.02% CHS) containing different concentrations of ivacaftor. The experiments
were also repeated with the further addition of 100 ng of CPM dye (7-Diethylamino-3-
(4′-Maleimidylphenyl)-4-Methylcoumarin), which acts as a reporter of solvent-exposed
cysteine residues [22,45–47]. The mixtures were loaded into capillaries at 4 ◦C, and the
latter were inserted into pre-chilled 16 well UNCLE capillary cassettes. Fluorescence
emission spectra were recorded between 200 nm and 700 nm with an excitation wavelength
of 266 nm. Static light scattering was recorded simultaneously using the 266 nm laser
source. Data were gathered between 16 ◦C and 90 ◦C with a stepwise increase in the
temperature (2 ◦C increments) followed by the recording of spectra for all the samples.
The total heating run required approximately 70 min. Raw data were exported and then
analyzed for tryptophan fluorescence, static light scattering, and CPM fluorescence using
the GraphPad Prism software package.
P-gp was initially buffer-exchanged into a detergent/glycerol-free buffer. The protein
was diluted to 1.1 mg/mL and incubated with 2 µM Ivacaftor (stock: 100 µM in DMSO)
for 30 min on ice. Quantifoil 200 or 400 Au grids with a 1.3-micron spacing pattern were
pre-treated prior to protein deposition, as described previously [21]. Briefly, grids were
surface-cleansed by multiple chloroform washes to eliminate hydrophobic residues, then
glow-discharged. An FEI Vitrobot MkIV was employed to facilitate sample vitrification
where 3 µL of protein was gently loaded onto the middle of the grid, immediately blotted
for 6 s, and flash-frozen in liquid ethane. Grids were assessed for specimen quality (i.e., ice
thickness, particle distribution, etc.) using a Polara G30 before shipping to the eBIC UK
National facility for high-resolution data acquisition on an FEI Titan Krios G2 microscope.
Data were recorded at 300 kV using a 20 mV energy filter and a Gatan K2 electron detector.
Images were acquired via the Volta phase plate [48] with a phase shift range between
0.15 and 0.8 radian and fixed defocus at −0.5 µm. A total of ~64 e− Å−2 were used over
40 frames spanning 10 s of exposure, and early and late frames were discarded. The
magnification was calibrated at 1.043 Å/pixel. A total of 2436 movie stacks were collected,
and beam-induced image shift was eliminated using MotionCorr2 [49].
The data processing of the 2436 images was entirely performed with cisTEM [50].
A total of 1030 images were eliminated for possessing poor CTF fitting profiles and exceed-
ing defocus values. The final set of 1406 images were divided into 2 similarly-populated
subsets (696i and 710i) to independently assess the reproducibility of the 2D classification
procedure. Ab-initio 3D reconstruction was performed employing ~50,000 particles derived
from several 2D classification runs of the 696i subsets. For each of the 5 classes that were
generated ab-initio, a PDB model was built using Molecular Dynamics Flexible Fitting
(MDFF) with NAMD 2.12, as detailed previously [21]. These models were used as a mea-
sure for comparing NBD separation in the five classes. Ab-initio 3D maps were then low
pass filtered to 10 Å and employed as starting templates for 3D refinement using the full
final set of 104,000 selected particles. After full 3D refinement of the maps, real-space refine-
ment of atomic models against the maps was performed within the PHENIX package [51],
with the MDFF-derived models used as the initial inputs. Half-maps and Fourier shell
correlation curves were generated employing the cisTEM and calculate_fsc routine. Local
resolution was also estimated using the program ResMap [52]. Rigid-docking of ivacaftor
was performed with the fit-in-map routine of UCSF Chimera [53] with a 5 Å-resolution
simulated map of ivacaftor atoms at 0.252 (7 × SD) and with optimization for overlap with
the experimental (additional) density in the P-gp central cavity. Fitting was subsequently
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minimized in Schrodinger’s Maestro (Schrödinger Release 2021-2: Maestro, Schrödinger,
LLC, New York, NY, USA, 2021), concomitantly allowing the rotamer adjustments of
neighboring residues. The final result was verified to maintain the occupancy of the cryo-
EM density. Nucleotide-binding pocket volumes of NBD1 and NBD2 were estimated by
summation of all voxels with lower than mean density values that were within 5 Å of a
positioned nucleotide. This was carried out with the matchmaker, color zone/split map, and
calculate volume and area functions of Chimera [52] and using the NBDs in the 6q81 P-gp
atomic model for positioning [21].
3. Results
3.1. Ivacaftor Binding Affinity of Murine P-gp
Ivacaftor has been identified as a competitive inhibitor of Hoechst 33,342 and digoxin
transport by human P-gp [22,23]. Ivacaftor stimulated human P-gp ATPase activity eight-
fold, suggesting it could also be considered as a transported allocrite, and its dissocia-
tion constant (KD) was estimated at 0.3 µM using a fluorescent dye transport assay with
the purified protein [22]. Similarly, a half-maximal inhibitory concentration (IC50) of
0.2 µM was estimated using an in-vivo assay [23]. We tested ivacaftor binding to murine
P-gp using various methods: Static light scattering and tryptophan fluorescence changes
yielded KD values of 0.2 µM (static light scattering) and ∼=1 µM (tryptophan fluores-
cence) (Supplementary Figure S1a,b). The binding of a sulfhydryl-reactive fluorescent dye
(7-Diethylamino- 3-(4’-Maleimidylphenyl)-4-Methyl-coumarin, CPM) to solvent-exposed
P-gp cysteine residues detected an unfolding transition between 30–50 ◦C that was sen-
sitive to ivacaftor with a KD estimated at 0.2 µM (Supplementary Figure S1c). Hence,
we concluded that the affinity for ivacaftor of murine P-gp was similar to human P-gp.
Moreover, the detection of light scattering changes upon ivacaftor binding implied confor-
mational changes in P-gp (e.g., due to an induced fit). Cryo-EM studies were subsequently
performed with a concentration of ivacaftor (2 µM) that was well above the KD, although
at this level it was still at a sub-stoichiometric ratio versus protein (estimated at 1.1 mg/mL,
or roughly 8 µM using a molecular mass of 150kDa for P-gp).
3.2. Cryo-EM of P-gp in the Presence of Ivacaftor
Images (2436) were recorded with the Volta phase plate, and after initial rejection of
poor quality images by eye, the contrast transfer function (CTF) of each was estimated. A
total of 1537 images gave CTF fits that were judged to be reliable whilst 868 were rejected at
this stage. A second criterion was applied to eliminate all images affected by excessive defo-
cus values, and a total of 131 further images were eliminated, with a final set of 1406 images
(Supplementary Figure S2). As expected, the P-gp particles were readily identifiable in the
images in the inward-facing conformation (Supplementary Figure S3), and automated par-
ticle picking was performed. Reference-free classification of the projections of the resulting
picked particles allowed a further pruning of the dataset by deleting any non-P-gp contam-
inants as well as small P-gp aggregates (Supplementary Figure S4). Several iterations of 2D
classification were completed to remove bad particles, and this was judged to be complete
when consistent 2D classes were obtained. The reproducibility of the 2D classification was
then assessed by splitting the dataset into two roughly equally populated sub-sets, which
individually showed the same outcome (Supplementary Figure S2).
Ab-initio 3D classes of the final P-gp dataset were generated from a subset of only
~50,000 particles, and these are shown in Supplementary Figure S5. At this early stage,
the 3D classes were relatively low resolution (~7 to 8 Å, as estimated by Resmap [54]).
Nevertheless, the two procedures clearly identified only inward-facing conformations,
even when five classes were allowed. Sets of particles displaying a wider separation of
the NBDs (classes a and c) were also picked out by the image processing package. For
each of the five low-resolution ab-initio maps, a PDB model was derived using Molecular
Dynamics Flexible Fitting (see Methods), and results were compared. Utilizing the center
of mass of the NBDs as a reference, classes b, d, and e showed a narrower separation of
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the NBDs (from 56 Å to 53 Å), while both classes a and c were found to have a wider
distance (60 Å). A moderate low-pass filter was applied to the ab-initio maps to avoid over-
fitting effects. CTF parameters were also further refined at this stage with per-micrograph
CTF fits using the dedicated cisTEM functionality for this. Refinement of the full dataset
(104,000 particles) starting with each of the five cisTEM ab-initio 3D classes was carried out
with a combination of auto- and manual-refinement, and an atomic model was generated
for each resulting refined 3D map using the PHENIX real space refinement routine [51].
The 3D maps, compared at a density threshold yielding a map volume of 153,000 Å3 are
displayed in Figure 1.
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The resolution of each map was assessed by splitting each d ta set in half d sepa-
rately refining e h half dataset. The correspondence between ha f-map was analyzed in
reciprocal space using Fourier shell correlation (FSC) as well as using the Resmap routine,
which c lculates loc l r solution in t maps [54,55]. The resolution assess ents as well as
other data pertaining to the five refined maps and the five atomic mod ls, re summarised
in Table 1. Each 3D map could be generated from fewer particles than in prior studies
of P-gp by cryo-EM [7,19,21] due to the high contrast of individual particle projections
produced with the Volta phase plate. However, the resolution achieved was estimated at
4–6 Å for all the maps (Table 1, Supplementary Figures S6–S8). Map resolution was not
correlated with particle numbers, consistent with the idea that, for structural studies of
unstabilized P-gp, intrinsic protein flexibility is likely to be a major factor in determining
the resolution achievable. Interestingly, map a displayed the lowest resolution of all the
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maps in the various tests employed, although the overall map-to-model correlation was
better (Table 1, Supplementary Figure S8). The Resmap analysis of map a, implied that
variation between the half-maps was mainly confined to the periphery of the NBDs and
the micelle (Supplementary Figure S6). Conversely, map e, with the closest approach of
the NBDs, was estimated to have the highest resolution by the Resmap algorithm [54] and
by Fourier shell correlation [55] (Supplementary Figure S7). In general, the map-to-model
correlation was lower for the NBDs compared to the TMDs in all maps (Supplementary
Figure S8).
Table 1. Summary of all the data for reciprocal space resolution assessment of the five maps as well
as the real-space correlation coefficient (CC) between the atomic model and the relevant map.
Parameter. Map a Map b Map c Map d Map e
Global Resolution (Å, FSC = 0.143) from unmasked
half maps (CisTEM)
5.4 4.3 4.3 4.2 4.2
Global Resolution (Å, FSC = 0.143) from map to model
fit (Phenix)
4.6 4.4 4.5 4.4 4.4
Resolution (Å) from Resmap with masked half maps
(Mean, Mode)
5.0, 4.0 4.5, 4.0 4.6, 4.0 4.5, 4.0 4.4, 4.0
CC map to model fit (mean from 1182 residues, Phenix) 0.73 0.67 0.63 0.69 0.65
3.3. Interpretation of the Differences between the 3D Maps
The various 3D maps showed the typical hinging of the two halves of the molecule,
giving differences in NBD separation, but it was apparent that NBD1 flexing relative to
the other P-gp domains was also being differentiated by the 3D classification algorithm:
NBD1 appeared to progressively rotate upwards towards the TMDs when one examines
maps a through e; (Figure 1, upper panel). Separation of NBD1 from NBD2 was greatest
for maps a and c; was narrower in maps b and d; whilst map e had the closest approach of
the NBDs (Figure 1, upper panel). As previously reported [21], densities assigned to the
N-terminus and to the end of the NBD1-NBD2 linker on the opposite side of the molecule
can be observed in the maps, especially map a (Figure 1 upper panel). Maps b and d
showed additional density for the linker but lacked density for the N-terminal region. In
contrast, map c showed the latter but appeared to lack the linker density. The density
for the extracellular loop (ECL) between TM helices 1 and 2 was weaker for maps c and
e, perhaps representing increased disorder in this loop, which may be core glycosylated
in the expression system used. These symmetry-breaking features of P-gp likely aid the
image processing via discrimination of projections of alternative 180◦-rotated orientations
of particles (Supplementary Figure S9).
The transmembrane regions (Figure 1, lower panel) also showed some subtle differ-
entiation between the five 3D maps. The diameter of the micelles in maps a and c are
noticeably larger; whilst map e has the smallest micelle, displaying some distortion from a
circular annulus. These differences may be a reflection of the degree of separation of the
two halves of the protein, which is greatest for maps a and c and least for map e. The latter
map shows the most compaction of the transmembrane α-helices. The transmembrane
regions of all five maps (Figure 1, lower panel) displayed the large central aqueous cavity
that connects to the cytoplasm as well as to the lipid bilayer (via the two lateral gaps formed
between TM helices 4 and 6 and between 10 and 12). These lateral gaps are a common
feature of type IV ABC transporters such as Sav1866, MsbA, and P-gp [56]. In P-gp the
central aqueous cavity has been found to house the binding sites for transported drugs and
inhibitors [7,14,16]. We, therefore, closely examined this cavity for evidence of ivacaftor
binding in the five maps. The criteria we used were that: (i) any features due to ivacaftor
should be visible at the same density level used for the protein (ii) that at this density level,
the feature(s) should be roughly rod-shaped, and (iii) have a continuous volume equivalent
in size to that expected for the drug. Finally, (iv) once fitted, the ivacaftor molecule should
not have serious clashes with nearby residues in a fitted P-gp atomic model (i.e., none that
could not be remedied with rotamer adjustment). Only map a contained a single feature
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that satisfied all these criteria (blue mesh, arrow, Figure 1, lower panel). All the other maps
did show small features in the aqueous central cavity (Figure 1 lower panel), especially at
lower density thresholds, but none of these met the first three criteria.
The additional density in the aqueous cavity of map a has a rocket-shape with two
fin-like protrusions at one end. At the opposite end to the protrusions, the density is close to
TM6, and in the fitted atomic model, it was close to F339 and Q343 (Figure 2). In accordance
with the last criterion, a single ivacaftor molecule could be fitted into this density, and the
overall rocket shape favored a fit with the 2,4 tert-butyl groups of the ivacaftor molecule
corresponding to the two ‘fins’ of the rocket-shaped density (CC = 0.960 vs. CC = 0.938 for
the 180◦ rotated version). The density is surrounded by residues contributed by TM helices
6, 10, and 12, and hence is positioned more in one lobe of the aqueous cavity (Figure 1).
Residues F339 and Q343 within TM6 in the refined atomic model are close enough to form
π-π (F339) and H-bonding (Q343) interactions with the quinoline group of the modeled
ivacaftor molecule (Figure 2), and the phenolic hydroxyl group of the drug could also
form H-bonding interactions with E871 within TM10 in this model. Small residues G868
and G985 in TM helices 10 and 12, respectively, allowed the fitting of the bulky tert-butyl
groups of ivacaftor without steric clashes with the protein. Although the cavity is aqueous,
I864, M872, L875 in TM10, and A981 in TM12 form a hydrophobic patch on its surface that
appears to be compatible with the positioning of the hydrophobic drug (Figure 2). K185 on
the cytoplasmic side of TM3 in the aqueous cavity is within ~10 Å of the additional density.
This is somewhat reminiscent of R933 in human CFTR [27].
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3.4. Conformational Changes Associated with the Additional Density
Assuming the additional density in map a is due to drug, then its presence is associated
with a wider separation of the two halves of P-gp, similar to observations for the co-crystal
structures of murine P-glycoprotein with the marine pollutant and P-gp inhibitor BDE-
100 [15,16,57]. Similarly, widening of the structure of the TmrAB heterodimeric peptide
exporter was associated with substrate-binding [13]. We, therefore, examined whether
other local changes in individual domains could be identified as being specific to map
a versus the other four maps. In this line of conjecture, we assumed that maps b to e
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were representative of multiple conformations of the apo-state. When map a’s atomic
model was compared to the one most closely matching it: map d model (rmsd =1.17 Å
for 1018 atom pairs within 2 Å, 1.46 Å overall 1182 atom pairs), a local bulging outwards
of the transmembrane helices were apparent (see Figure 3), similar to that observed for
TmrAB [13]. When we compared map a’s model to that of map e (which was the most
different—rmsd 1.40 Å over 519 atom pairs within 2 Å, 2.64 Å overall 1182 atom pairs), the
outwards bulging of the TM helices upon ivacaftor accommodation was more noticeable.
In both cases, TM helices 1, 2, 7, and 8 move most whilst helices 6 and 12 move little
(Figure 3b,c), and the bulge of the TMDs resulted in a wider separation of the NBDs. As
previously mentioned, NBD1 also showed a downward rotation away from the TMDs
(Figure 3).
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Figu e 3. Allos ery: (a) Cartoon representation of conformational hanges discussed with r gard to
the presence of ivacaftor with P-gp. Left shows the assu ed apo-state and indicates the movements
of the TMDs and NBDs associated with the drug-bound state (right): (i) the TMD helices bow
outwards and the central cavity enlarges. (ii) The NBDs become more separated. (iii) NBD1 rotates
downwards. The small darker circles indicate hinge points between domains. (b,c) outward bulge of
the TMDs in the atomic model from map a (pink ribbon) vs. models from map e (green) and map
d (blue). The additional density associated with ivacaftor in map a is shown (red mesh). Panel b
is a section viewed along the membrane plane; panel c is a section viewed from the extracellular
surface. (d) NBD1 and NBD2 in experimental maps a and d viewed from between the NBDs (blue
and purple semi-transparent surfaces). The real-space refined atomic models for P-gp fitted to the
maps are in red and blue, respectively. The nucleotide-binding cavity is indicated with the red mesh
and its volume is given in cubic Ångstrom.
The net result of this movement of the NBDs in the atomic models was a downward
(cytoplasmic) shift of the Walker A and B regions relative to intracellular loops 1 and
4 that connect NBD1 from the TMD, and in map a this is manifested as an opening up
of the nucleotide-binding site in NBD1 (Figure 3d). Similar changes but with a smaller
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magnitude, were also observed for NBD2 in the maps and atomic models. Caution must
be exercised when extrapolating from atomic models that have been fitted to worse-than-
atomic resolution maps, but if these conformational shifts in the NBDs are valid, then they
may be reflective of allosteric changes that lead to increased ATPase activity of P-gp upon
binding of a transport substrate.
4. Discussion
Structural data for 3D conformations of P-gp were obtained with the Volta phase
plate; and with this methodology the resolution of the 3D information obtained was
around 6-4 Ångstrom. Whether these resolution limitations can be overcome with a larger
dataset remains to be established. The use of sub-stoichiometric levels of ligand may be
a suitable approach in future cryo-EM studies, provided that ligand–protein complexes
can be distinguished from ligand-free protein on the basis of different conformational
status and/or by a sufficiently large additional density due to the ligand. Clearly, atomic
details of ligand binding mode will depend on close to atomic resolution data, but the
overall location of the ligand and some modeling of likely binding modes will be possible
at intermediate resolution, as described here and in other studies for various other proteins
and ligands [30–42].
Drug and inhibitor binding locations in P-gp have previously been studied for both
mouse and human versions of the protein [8,9,15,16,58] as well as for a human/mouse
chimeric construct [7]. For mouse P-gp, published structural data from X-ray crystallog-
raphy is available for cyclic peptide inhibitors and for a marine pollutant BDE-100 that
is also thought to act as an inhibitor of the protein [15,16]. For human P-gp, cryo-EM
data are available for well-characterized substrates such as taxol [8,9] and vincristine [8]
and also for some inhibitors such as elacridar, zosuquidar, and tariquidar [8]. Ivacaftor
has been shown in-vitro to stimulate P-gp ATPase activity and to reduce transport by
P-gp of Hoechst 33342 [22]. In humans, ivacaftor administration caused increased blood
digoxin levels [23], implying inhibition of P-gp. These studies suggest that ivacaftor can
compete with Hoechst 33342 transport and digoxin transport by P-gp, hence ivacaftor
could be transported by P-gp. Alternatively, the data could be consistent with ivacaftor
acting as a non-competitive or uncompetitive inhibitor of the protein’s transport (but
not ATPase) function. The Hoechst 33342 binding site (H-site) has been modeled to be
asymmetrically–located in P-gp [59,60], but this position is in the opposite lobe of the
internal cavity compared to the modeled site for digoxin (D-site) [60], and the density
associated with ivacaftor described here. Hence from the data and models, one could
propose that ivacaftor may compete for both digoxin binding and transport. Whereas for
Hoechst 33342, transport, but not binding, would be affected by ivacaftor presence. These
suggestions remain to be tested experimentally.
A comparison of murine P-gp models both with and without bound compounds is
shown in Figure 4, panels a–c. Their conformations are similar to the murine P-gp model for
map a that is described here, with root mean squared deviation (rmsd) between the main
chain Cα atoms of the models of around 4 Å over 1179 comparisons (i.e., not including
disordered linker and N- and C-terminii atoms). When these various atomic models are
superimposed (Figure 4, upper panels), the positions of the inhibitors and drug (ivacaftor)
are all found within the central aqueous cavity. However, the BDE-100 and cyclic peptide
inhibitors appear to be located further towards the extracellular side of the membrane.
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Figure 4. Location of drugs and inhibitors within the P-gp central binding cavity: (a–c): Murine P-gp models. Purple
ribbon is the atomic model for map a in this paper (ivacaftor- red): yellow, PDBID 4q9h- apo-state; cyan, 4q9j- with QZ-Val;
orange, 4q9i-QZ-Ala; taupe, 4q9k-QZ-Leu; green, 4q9l-QZ-Phe; turquoise, 4xwk-BDE-100. The o ele osition of ivacaftor
sits further towards the cytoplasm than the various inh bitor shown. Trans-membrane helices are numb red according
to their position in the P-gp sequence. (a,b) are orthogonal views along the membr plane; (c) is the view from the
cytoplasm. Curved arrows indicate the 90◦ rotations involved. (d–f): Human and human/mouse chimera P-gp: no drug
(6fn4, yellow ribbon); with zosuquidar (6fn1, green ribbon, green drugs, and black drugs-7a6f); tariquidar (7a6e, pink drugs);
vincristine (7a69, cyan drug); taxol (6qex, blue drug); elacridar (7a6c, orange drugs). Wider separation of the murine NBDs
necessitated alignment of the N- and C-terminal arms of the model (this paper, purple ribbon, red drug) with the human
P-gp structures. Where major differences exist between the paths of transmembrane helices in human and murine models,
they are numbered in both purple and green font.
A comparison of the mouse/ivacaftor P-gp model with human and human/mouse
chimera P-gp models in the presence and absence of other small molecules is shown in
Figure 4, panels d–f. Separate alignment of the two ‘wings’ of the inward-facing conforma-
tion of the mouse/ivacaftor structure was required for this comparison because the human
and chimera P-gp models all show a closer approach of the NBDs. In these comparisons,
both substrates and inhibitors co-localize to the same approximate position within the
central cavity. As discussed by Nosol et al. [8], whilst the P-gp inhibitors display two
separate molecules in the cavity, the transported substrates (and ivacaftor) display only
one molecule in the cavity. Density associated with ivacaftor in map a is consistent with a
single molecule, but again, in this comparison, it would be located closer to the cytoplasmic
side of the membrane than the other compounds, with the exception of one of the elacridar
molecules (orange stick representation, Figure 4).
Taken together, the data for ivacaftor is equivocal: the single density observed would
imply that ivacaftor shares P-gp substrate characteristics, whilst its overall location in
one lobe and over towards the cytoplasmic leaflet of the bilayer is suggestive of binding
characteristics of an inhibitor according to the work of Nosol et al. [8]. It seems possible that
the low concentration/stoichiometry of the drug employed in this study may result in a
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single bound ivacaftor molecule at a higher affinity site, even if it were an inhibitor with two
potential sites. However, it should be noted that not all inhibitors appear to bind in the same
position: The cyclic peptide inhibitors and BDE-100 studied with murine P-gp occupied
a location different from the elacridar, tariquidar, and zosuquidar inhibitors [14,15]. In
addition, of note is that in the human P-gp models, transmembrane helices 4 and 10, were
kinked inwards and appear to partially close off the internal cavity on the cytoplasmic
side. This behavior has not been observed thus far in the murine P-gp models (Figure 4).
The closest approach of the two halves of the human and chimera P-gp atomic models is
also noteworthy, although this may result from different solubilization methods employed
(lipids in the nanodiscs for human P-gp; detergent in micelles for murine and chimera
P-gp). Whether these differences between human and murine P-gp structures represent
interspecies variation, or instead alternative conformational states in the transport cycle
remains to be established. At first sight, it would seem somewhat counterintuitive that
drug binding to P-gp would induce a further separation of NBDs, rather than bringing
them towards the NBD dimerized and outward-facing state. However, other studies
have also detected similar conformational shifts (e.g., [13,15,16], including P-gp structures
co-crystallized with BDE-100. We would propose that the opening of the NBD1 nucleotide-
binding site may be a precursor to further conformational shifts induced by nucleotide that
then promote the formation of the outward-facing state.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/membranes11120923/s1, Figure S1: Murine P-gp affinity for ivacaftor measured by ther-
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Assessment of map a resolution; Figure S7: Different assessments of the resolution of all five maps;
Figure S8: Comparison of model-to-map fits; Figure S9: Asymmetry in P-gp. Examples of major
asymmetrical features that distinguish between the N- and C-terminal halves of the protein.
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